New Age Alpha Advisors LLC Invests $1.37 Million in Lantheus Holdings, Inc. (NASDAQ:LNTH)

New Age Alpha Advisors LLC bought a new position in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The firm bought 15,259 shares of the medical equipment provider's stock, valued at approximately $1,365,000.

Other large investors have also recently modified their holdings of the company. Geode Capital Management LLC lifted its holdings in Lantheus by 2.0% in the third quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider's stock worth $184,798,000 after buying an additional 32,551 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Lantheus by 47.7% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,684 shares of the medical equipment provider's stock valued at $1,041,000 after purchasing an additional 3,772 shares during the period. Empirical Asset Management LLC bought a new stake in shares of Lantheus during the fourth quarter valued at approximately $323,000. Focus Financial Network Inc. purchased a new stake in Lantheus in the fourth quarter worth $292,000. Finally, Harbor Capital Advisors Inc. raised its holdings in Lantheus by 12.8% in the fourth quarter. Harbor Capital Advisors Inc. now owns 145,379 shares of the medical equipment provider's stock worth $13,006,000 after purchasing an additional 16,466 shares in the last quarter. Institutional investors own 99.06% of the company's stock.

Lantheus Stock Down 6.5 %

Shares of NASDAQ LNTH traded down $6.29 during midday trading on Friday, hitting $90.92. The stock had a trading volume of 1,158,346 shares, compared to its average volume of 944,377. The company has a market cap of $6.23 billion, a P/E ratio of 15.13 and a beta of 0.38. Lantheus Holdings, Inc. has a 52 week low of $58.46 and a 52 week high of $126.89. The business's 50 day moving average is $93.31 and its 200-day moving average is $96.18.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.57 by ($0.23). The company had revenue of $391.11 million for the quarter, compared to analysts' expectations of $376.61 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. As a group, analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. The Goldman Sachs Group began coverage on shares of Lantheus in a research report on Wednesday, December 18th. They issued a "buy" rating and a $143.00 target price on the stock. B. Riley cut their price objective on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating on the stock in a report on Friday, March 21st. Truist Financial lifted their target price on shares of Lantheus from $120.00 to $127.00 and gave the company a "buy" rating in a report on Thursday, February 27th. Finally, JMP Securities restated a "market outperform" rating and issued a $112.00 price target on shares of Lantheus in a research note on Tuesday, January 14th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $129.43.

Insider Buying and Selling

In related news, Director Mary Anne Heino sold 53,107 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the sale, the director now directly owns 440,399 shares in the company, valued at approximately $41,551,645.65. The trade was a 10.76 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director James H. Thrall sold 1,000 shares of the company's stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total transaction of $94,760.00. Following the sale, the director now directly owns 33,207 shares of the company's stock, valued at approximately $3,146,695.32. This represents a 2.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 64,109 shares of company stock valued at $6,110,806 over the last 90 days. Company insiders own 2.00% of the company's stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.